Syndax Pharmaceuticals, Inc(NASDAQ:SNDX) 
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treat...
Website: http://www.syndax.com
Founded: 2005
Full Time Employees: 35
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 12.07
H 12.17
L 11.09
C 11.25
V 1,817,602
10EMA 11.25
20EMA 11.25
60EMA 11.25
120EMA 11.25
250EMA 11.25